Collect

One 2.7 mL Sodium Citrate (Blue) Tube

Unacceptable Conditions

Aliquot type not properly identified; not Frozen; clotted specimen

Storage/Transport Temperature

1 mL plasma Frozen

Stability (from collection to initiation)

Ambient: 4 hrs (2 hrs if spun/uncapped)

Frozen: One week

Performed

Sun-Sat

Remarks

Draw one full light blue top Tube (blood-to-anticoagulant is critical). Refer to the 'Hemostasis/Thromobosis Specimen Collection' link below for processing information. Separate platelet-poor plasma from cells ASAP.

Hemostasis_Thrombosis_Specimen_Collection_7_17_13.pdf 

Department

Coagulation

Performed

Sun-Sat

Methodology

Chromogenic

Interpretive Data

Laboratory monitoring with Anti-factor Xa activity is not necessary for most patients. Metabolism of the drug may be altered in patients at the extremes of body size, age and in those with renal disease. Dosage levels represent observed fondaparinux levelsof patients from clinical trials.

 

For prophylactic regimens (i.e. 2.5 mg daily dose):

Peak concentration 3 hours following dose: 0.39-0.50 mg/L

Minimal concentration (immediately prior to dose): 0.14-0.19 mg/L

 

For full anticoagulation (5.0-10.0 mg daily weight-adjusted dose):

Peak concentration 3 hours following dose: 1.20-1.26mg/L

Minimal concentration (immediately prior to dose): 0.46-0.62 mg/L

 

It is recommended that the assay be performed approximately 3 hours after administration of the daily dose.

CPT Codes

85130

Collection

Collect

One 2.7 mL Sodium Citrate (Blue) Tube

Unacceptable Conditions

Aliquot type not properly identified; not Frozen; clotted specimen

Storage/Transport Temperature

1 mL plasma Frozen

Stability (from collection to initiation)

Ambient: 4 hrs (2 hrs if spun/uncapped)

Frozen: One week

Performed

Sun-Sat

Remarks

Draw one full light blue top Tube (blood-to-anticoagulant is critical). Refer to the 'Hemostasis/Thromobosis Specimen Collection' link below for processing information. Separate platelet-poor plasma from cells ASAP.

Hemostasis_Thrombosis_Specimen_Collection_7_17_13.pdf 

Department

Coagulation

Ordering

Performed

Sun-Sat

Methodology

Chromogenic

Result Interpretation

Interpretive Data

Laboratory monitoring with Anti-factor Xa activity is not necessary for most patients. Metabolism of the drug may be altered in patients at the extremes of body size, age and in those with renal disease. Dosage levels represent observed fondaparinux levelsof patients from clinical trials.

 

For prophylactic regimens (i.e. 2.5 mg daily dose):

Peak concentration 3 hours following dose: 0.39-0.50 mg/L

Minimal concentration (immediately prior to dose): 0.14-0.19 mg/L

 

For full anticoagulation (5.0-10.0 mg daily weight-adjusted dose):

Peak concentration 3 hours following dose: 1.20-1.26mg/L

Minimal concentration (immediately prior to dose): 0.46-0.62 mg/L

 

It is recommended that the assay be performed approximately 3 hours after administration of the daily dose.

Administrative

CPT Codes

85130